Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024)
Acumen Pharmaceuticals' (ABOS) quarterly Operating Leases came in at $185000.0 in Q3 2024, down 15.53% quarter-over-quarter from $219000.0 in Q2 2024.
Powered by 
Analysis
Acumen Pharmaceuticals (ABOS) Operating Leases (2022 - 2024) Analysis & Trends
Acumen Pharmaceuticals has disclosed Operating Leases across 3 years of filings, most recently posting $185000.0 for Q3 2024.
- In Q3 2024, Operating Leases changed N/A year-over-year to $185000.0; the TTM figure through Sep 2024 stood at $185000.0 (changed N/A YoY), while the FY2023 annual figure was $284000.0, changed N/A from the prior year.
- Operating Leases came in at $185000.0 for Q3 2024 at Acumen Pharmaceuticals, down from $219000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $284000.0 in Q4 2023 to a low of $133000.0 in Q3 2022.
- Average Operating Leases over 3 years is $205857.1, with a median of $201000.0 recorded in 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Acumen Pharmaceuticals | 205.91 Mn | 205.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 185,000.00 |
| Jun 30, 2024 | 219,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 284,000.00 |
| Sep 30, 2022 | 133,000.00 |
| Jun 30, 2022 | 167,000.00 |
| Mar 31, 2022 | 201,000.00 |